Abstract
The recombinant analogue of human glucagon-like peptide-2 (GLP-2) teduglutide (Gattex®, Revestive®) is a novel therapy for short bowel syndrome (SBS). GLP-2 is a naturally occurring hormone that regulates the growth, proliferation and maintenance of cells lining the gastrointestinal tract. Subcutaneous teduglutide is the first long-term medical therapy approved for the treatment of adult patients with SBS who are dependent on parenteral support (parenteral nutrition and/or intravenous fluids). In a pivotal, double-blind, multicentre, phase III study in adult patients with SBS who were dependent on parenteral support, a significantly higher proportion of teduglutide 0.05 mg/kg/day recipients than placebo recipients achieved at least a 20 % reduction from baseline in weekly parenteral support volume at week 20 and maintained at week 24 (primary endpoint). The overall mean reduction in weekly parenteral support volume from baseline was greater in patients who received teduglutide compared with those who received placebo. Additionally, more teduglutide-treated patients achieved at least a one-day reduction in parenteral support than those receiving placebo. Subcutaneous teduglutide had an acceptable tolerability profile; the most frequently reported adverse events were of gastrointestinal origin, consistent with the underlying disease condition and the known mechanism of action of teduglutide.
Similar content being viewed by others
References
Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology. 2003;124(4):1111–34.
O’Keefe SJ, Buchman AL, Fishbein TM, et al. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol. 2006;4(1):6–10.
Misiakos EP, Macheras A, Kapetanakis T, et al. Short bowel syndrome: current medical and surgical trends. J Clin Gastroenterol. 2007;41(1):5–18.
Drozdowski LA, Clandinin MT, Thomson AB. Morphological, kinetic, membrane biochemical and genetic aspects of intestinal enteroplasticity. World J Gastroenterol. 2009;15(7):774–87.
Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001;120(4):806–15.
Nightingale J, Woodward JM. Guidelines for management of patients with a short bowel. Gut. 2006;55(Suppl 4):iv1–12.
Seidner DL, Schwartz LK, Winkler MF, et al. Increased intestinal absorption in the era of teduglutide and its impact on management strategies in patients with short bowel syndrome-associated intestinal failure. JPEN J Parenter Enteral Nutr. 2013;37(2):201–11.
Steiger E. Guidelines for pharmacotherapy, nutritional management, and weaning parenteral nutrition in adult patients with short bowel syndrome: introduction. J Clin Gastroenterol. 2006;40(Suppl 2):S73–4.
Oley Foundation. North American home parenteral and enteral nutrition patient registry annual report. 1994. http://www.oley.org/documents/Patient_Registry_AnnualReportFinal.pdf. Accessed 8 May 2013.
McMellen ME, Wakeman D, Longshore SW, et al. Growth factors: possible roles for clinical management of the short bowel syndrome. Semin Pediatr Surg. 2010;19(1):35–43.
Food and Drug Administration. FDA briefing information for the 16 October 2012 meeting of the GastroIntestinal Drugs Advisory Committee. 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM323504.pdf. Accessed 8 May 2013.
Scolapio JS. Short bowel syndrome: recent clinical outcomes with growth hormone. Gastroenterology. 2006;130(2 Suppl 1):S122–6.
NPS Pharmaceuticals. Gattex (teduglutide): US prescribing information. 2012. http://www.npsp.com/file_depot/0-10000000/0-10000/262/folder/2023/Gattex_PI-IFU_FINAL_2012-12-21.pdf. Accessed 8 May 2013.
European Medicines Agency. Revestive (teduglutide): summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002345/WC500132926.pdf. Accessed 8 May 2013.
Marier JF, Beliveau M, Mouksassi MS, et al. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol. 2008;48(11):1289–99.
Marier J-F, Mouksassi M-S, Gosselin NH, et al. Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn’s disease. J Clin Pharmacol. 2010;50(1):36–49.
Hartmann M, Timmer W, Schultz A, et al. A thorough QT study of teduglutide in healthy subjects. Clin Pharmacol Drug Dev. 2012;1(2):57–66.
Berg J, Kim E, Li Y, et al. A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the effects of teduglutide on gastric emptying in healthy subjects [abstract no. Sa1959]. Digestive Disease Week 2012 (DDW); 20–22 May 2012; San Diego.
Berg JK, Kim EH, Li B, et al. A randomized, double-blind, placebo-controlled study to assess the effects of teduglutide on gastric emptying in healthy subjects [abstract no. 1520397]. American Society for Parenteral and Enteral Nutrition (ASPEN) Clinical Nutrition Week 2013 (CNW13); 9–12 Feb 2013; Phoenix.
Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54(9):1224–31.
Jeppesen PB, Gilroy R, Pertkiewicz M, et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011;60(7):902–14.
Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473–81.
Wallis K, Walters JRF, Gabe S. Short bowel syndrome: the role of GLP-2 on improving outcome. Curr Opin Clin Nutr Metab Care. 2009;12(5):526–32.
Van Citters GW, Lin HC. The ileal brake: a fifteen-year progress report. Curr Gastroenterol Rep. 1999;1(5):404–9.
Tappenden KA, Edelman J, Joelsson B. Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome. J Clin Gastroenterol. 2013. doi:10.1097/MCG.0b013e3182828f57
Papadia C, Sherwood RA, Kalantzis C, et al. Plasma citrulline concentration: a reliable marker of small bowel absorptive capacity independent of intestinal inflammation. Am J Gastroenterol. 2007;102(7):1474–82.
O’Keefe SJ, Jeppesen PB, Gilroy R, et al. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel syndrome intestinal failure. Clin Gastroenterol Hepatol. 2013. doi:10.1016/j.cgh.2012.12.029.
Nave R, Halabi A, Herzog R, et al. Pharmacokinetics of teduglutide in subjects with renal impairment. Eur J Clin Pharmacol. 2012. doi:10.1007/s00228-012-1455-7.
Schwartz L, Fujioka K, Jeppesen PB, et al. Continued improvement and maintenance of parenteral nutrition and/or intravenous fluid support volume reduction in patients with long-term teduglutide treatment: results of an ongoing long-term open-label study [abstract no. 1520168 plus poster]. American Society for Parenteral and Enteral Nutrition (ASPEN) Clinical Nutrition Week 2013 (CNW13); 9–12 Feb 2013; Phoenix.
Jeppesen PB, Pertkiewicz M, Forbes A, et al. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide - analyses from a randomised, placebo-controlled study. Clin Nutr. 2013. doi:10.1016/j.clnu.2013.03.016.
Gilroy R, Allard J, Jeppesen PB, et al. Treatment out to 1 year with a GLP-2 analog, teduglutide, safely reduces parenteral nutrition (PN) needs in PN-dependent short bowel syndrome patients [abstract no. 273]. Am J Gastroenterol. 2008;103(s1):S105.
Fujioka K, Seidner DL, Delmaestro E, et al. Long-term safety and tolerability of teduglutide in patients with intestinal failure associated with short bowel syndrome: combined data from phase III trials [abstract no. 1520553 plus poster]. American Society for Parenteral and Enteral Nutrition (ASPEN) Clinical Nutrition Week 2013 (CNW13); 9–12 Feb 2013; Phoenix.
NPS Pharmaceuticals. A one-year, open-label study with teduglutide for subjects who completed study CL0600-021 (STEPS 3) (ClinicalTrials.gov identifier NCT01560403) US National Institutes of Health, ClinicalTrials.gov. 2012. http://www.clinicaltrials.gov/ct2/show/NCT01560403. Accessed 8 May 2013.
European Medicines Agency. Revestive: EPAR-Public assessment report. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002345/WC500132928.pdf. Accessed 8 May 2013.
NPS Pharmaceuticals. Risk evaluation and mitigation strategy (REMS). 2013. http://www.gattexrems.com/. Accessed 8 May 2013.
Buchman AL. Teduglutide and short bowel syndrome: every night without parenteral fluids is a good night. Gastroenterology. 2012;143(6):1416–20.
Disclosure
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Additional information
The manuscript was reviewed by: L. Matarese Division of Gastroenterology, Hepatology and Nutrition, East Carolina University, Greenville, North Carolina, USA; E. P. Misiakos Attikon University Hospital, Athens, Greece; A. Shatnawei Department of Gastroenterology and Hepatology, Digestive Disease Institute, The Cleveland Clinic, Cleveland, Ohio, USA; D. L. Sigalet Department of Surgery, Alberta Children’s Hospital & University of Calgary, Calgary, Alberta, Canada; E. Steiger Nutrition Support and Vascular Access Department, Cleveland Clinic Foundation, Cleveland, Ohio, USA; J. S. Thompson Department of Surgery, University Nebraska Medical Center, Omaha, Nebraska, USA; J. Woodward Department of Gastroenterology, Addenbrooke’s Hospital, Cambridge, UK.
Rights and permissions
About this article
Cite this article
Burness, C.B., McCormack, P.L. Teduglutide: A Review of its Use in the Treatment of Patients with Short Bowel Syndrome. Drugs 73, 935–947 (2013). https://doi.org/10.1007/s40265-013-0070-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-013-0070-y